Search Results
20 results found-
These changes were brought into effect counter (OTC) securities market in the United States.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
CATIONORM® OTC ophthalmic treatment for dry eyes NR Australia RYALTRIS® Nasal spray for treatment of symptoms of allergic rhinitis NR Australia and rhino-conjunctivitis *
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
ST. GALLEN, SWITZERLAND, March 28, 2024 / PRNewswire / -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
A ordinary course of trading in the Over-The-Counter (OTC) significant foreign shareholding is one where a foreign person market in the US.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
Each vial of CSL830 contained 150 to 240 mg protein, 25.5 to 34.5 mg glycine, 4.5 to 10.5 mg trisodium citrate dihydrate, and 21 to 30 mg sodium chloride.
https://www.csl.com/-/media/shared/documents/clin-trials/csl830_2001_synopsis_27jun2013_public.pdf -
Adverse events (AEs) leading to premature study discontinuation. •
https://www.csl.com/-/media/shared/documents/clin-trials/csl830_3002_synopsis_15mar2018_public.pdf -
About Bio Products Laboratory (BPL) Recognising the power of plasma and with over 60 years heritage in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally.
https://newsroom.csl.com/2020-04-06-Global-Plasma-Leaders-Collaborate-to-Accelerate-Development-of-Potential-COVID-19-Hyperimmune-Therapy -
Berinert® S.C. Injection 2000" is a twice-weekly subcutaneous injection formulation of Berinert 60 IU/kg that can be self-administered at home. "
https://newsroom.csl.com/2022-09-26-CSL-Receives-Manufacturing-and-Marketing-Authorization-in-Japan-for-Berinert-R-S-C-Injection-2000,-as-a-Medicine-for-prevention-of-Acute-Hereditary-Angioedema-HAE-attacks -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline -
About Hizentra ® Registered in more than 60 countries, Hizentra is the most prescribed subcutaneous immunoglobulin for primary immunodeficiency (PI) in the U.S. It has a proven track record of safety, efficacy, and tolerability.
https://newsroom.csl.com/2023-04-18-CSL-Behring-Receives-FDA-Approval-for-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-50mL-Prefilled-Syringe